m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05536
 [1]
m6A modification MIR576 MIR576 FTO Demethylation : m6A sites Direct Enhancement Non-coding RNA miR-576 CDK6  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target microRNA 576 (MIR576)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 576 (MIR576) microRNA View Details
Regulated Target Cyclin-dependent kinase 6 (CDK6) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary FTO promoted bladder cancer cell proliferation, migration and invasion via the FTO/microRNA 576 (MIR576)/Cyclin-dependent kinase 6 (CDK6) pathways in an m6A-dependent manner.
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Cell Process Cell proliferation
In-vitro Model
 T24 Bladder carcinoma Homo sapiens CVCL_0554
5637 Bladder carcinoma Homo sapiens CVCL_0126
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Approximately 1 × 107 stably transfected T24 cells were subcutaneously injected into BALB/c nude mice. The length (L) and width (W) of the tumours were measured weekly using callipers, while their volume was calculated using the equation: V = (L × W2)/2. After 4 weeks of injections, the mice were euthanised, and the tumour tissues were removed and weighed.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cyclin-dependent kinase 6 (CDK6) 32 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Palbociclib Approved [2]
Synonyms
571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
    Click to Show/Hide
MOA Modulator
Activity IC50 = 15 nM
External Link
CID: 5330286
TTD: D00UZR
DrugBank: DB09073
 Compound Name Ribociclib Succinate Approved [3]
Synonyms
1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739
    Click to Show/Hide
MOA Modulator
External Link
CID: 57334219
TTD: D01HVT
 Compound Name LY2835219 Approved [4]
Synonyms
Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);
    Click to Show/Hide
MOA Modulator
Activity IC50 = 1.9 nM
External Link
CID: 46220502
TTD: D05SBO
DrugBank: DB12001
 Compound Name Trilaciclib Approved [5]
Synonyms
G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 68029831
TTD: D0AP9E
DrugBank: DB15442
 Compound Name Apremilast Approved [6]
Synonyms
Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11561674
TTD: D07ESC
DrugBank: DB05676
 Compound Name LEE011 Phase 3 [7]
Synonyms
Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013
    Click to Show/Hide
MOA Modulator
Activity IC50 = 6 nM
External Link
CID: 44631912
TTD: D08MXP
DrugBank: DB11730
 Compound Name G1T38 Phase 2 [8]
Synonyms
YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 86269224
TTD: D0WU1O
 Compound Name GLR2007 Phase 1/2 [9]
MOA Inhibitor
External Link
TTD: D4IS0G
 Compound Name FCN-437 Phase 1/2 [10]
MOA Inhibitor
External Link
TTD: D8ZV2Q
 Compound Name NUV-422 Phase 1/2 [11]
MOA Inhibitor
External Link
TTD: D70HZT
 Compound Name G1T28-1 Phase 1 [4]
MOA Modulator
External Link
TTD: D01XZG
 Compound Name RGT-419B Phase 1 [12]
MOA Inhibitor
External Link
TTD: DYH94Z
 Compound Name FN-1501 Phase 1 [13]
Synonyms
1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72195175
TTD: DKCU40
 Compound Name PMID25726713-Compound-49 Patented [14]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D07TVO
 Compound Name PMID25726713-Compound-51 Patented [14]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0KH7Q
 Compound Name Isoquinoline 1,3-dione derivative 1 Patented [15]
Synonyms
PMID26161698-Compound-49
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 nM
External Link
TTD: D0W4MN
 Compound Name PMID25726713-Compound-48 Patented [14]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0WJ3W
 Compound Name PMID25726713-Compound-47 Patented [14]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0X5VI
 Compound Name PMID25726713-Compound-50 Patented [14]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0Y8JF
 Compound Name Oxazolyl methylthiothiazole derivative 1 Patented [15]
Synonyms
PMID26161698-Compound-52
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
CID: 25195503
TTD: D0M5DX
 Compound Name INOC-005 Preclinical [16]
Synonyms
Capridine beta (prostate cancer), Prostagenics
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07ZJC
 Compound Name CYC-103 Terminated [17]
Synonyms
Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0Y6HA
 Compound Name PD-0183812 Terminated [18]
Synonyms
PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330258
TTD: D0Z0KD
 Compound Name Fascaplysin Investigative [18]
Synonyms
Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3400 nM
External Link
CID: 73292
TTD: D09OAH
 Compound Name Deschloroflavopiridol Investigative [18]
MOA Inhibitor
External Link
CID: 102397231
TTD: D0CI3C
 Compound Name RGB-286147 Investigative [19]
Synonyms
pyrazolopyrimidone analog, RGB-286147
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135473382
TTD: D0J4ON
 Compound Name Chrysin Investigative [20]
Synonyms
480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6000 nM
External Link
CID: 5281607
TTD: D01UYI
DrugBank: DB15581
 Compound Name 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative [21]
Synonyms
Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 850 nM
External Link
CID: 5281614
TTD: D0MF5Y
DrugBank: DB07795
 Compound Name APIGENIN Investigative [20]
Synonyms
520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1700 nM
External Link
CID: 5280443
TTD: D00RIX
DrugBank: DB07352
 Compound Name 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative [22]
Synonyms
1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10946795
TTD: D00NYT
 Compound Name 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative [22]
Synonyms
2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 2752461
TTD: D0C3WY
 Compound Name 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative [22]
Synonyms
CHEMBL372076; SCHEMBL3822337
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11572699
TTD: D0EK0G
2C94: Bladder cancer 83 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Enfortumab vedotin Phase 3 [23]
Synonyms
Padcev
    Click to Show/Hide
External Link
TTD: DAG87H
 Compound Name Atezolizumab Approved [8]
External Link
TTD: D0YM2K
 Compound Name Halaven Phase 1/2 [8]
Synonyms
Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
    Click to Show/Hide
External Link
CID: 17755248
TTD: D0XQ5X
 Compound Name RG-7446 Approved [24]
External Link
TTD: D0OZ4J
 Compound Name Pemigatinib Approved [8]
Synonyms
Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
    Click to Show/Hide
External Link
CID: 86705695
TTD: D0O6UY
DrugBank: DB15102
 Compound Name Erdafitinib Approved [25]
Synonyms
1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino
    Click to Show/Hide
External Link
CID: 67462786
TTD: D0NW0T
DrugBank: DB12147
 Compound Name Hexyl aminolevulinate Approved [26]
Synonyms
Hexvix (TN)
    Click to Show/Hide
External Link
CID: 6433082
TTD: D0AY9Q
 Compound Name BCG vaccine Approved [26]
Synonyms
OncoTice; TiceBCG; BCG vaccine, Organon
    Click to Show/Hide
External Link
TTD: D0A8LZ
 Compound Name Valrubicin Approved [27]
Synonyms
Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
    Click to Show/Hide
External Link
CID: 454216
TTD: D07IPB
DrugBank: DB00385
 Compound Name Vicineum Phase 3 [28]
Synonyms
Oportuzumab monatox
    Click to Show/Hide
External Link
TTD: DRP4Q9
 Compound Name Sasanlimab Phase 3 [29]
Synonyms
PF-06801591
    Click to Show/Hide
External Link
TTD: DP2Z0X
 Compound Name CG0070 Phase 3 [30]
Synonyms
CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys
    Click to Show/Hide
External Link
TTD: D7EZ0H
 Compound Name Nadofaragene firadenovec Phase 3 [8]
External Link
TTD: D0X4TK
 Compound Name Oportuzumab monatox Phase 3 [30]
External Link
TTD: D0OF1R
 Compound Name Apaziquone Phase 3 [31]
Synonyms
EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin
    Click to Show/Hide
External Link
CID: 5813717
TTD: D0FP0R
DrugBank: DB12593
 Compound Name Tesetaxel Phase 2 [32]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name EN3488 Phase 3 [33]
External Link
TTD: D09KHE
 Compound Name NKTR 214 Phase 3 [30]
External Link
TTD: D02QQE
 Compound Name Ramucirumab Phase 3 [8]
External Link
TTD: D01QWT
 Compound Name Vicinium Phase 3 [8]
External Link
TTD: D00RTC
 Compound Name ICP-192 Phase 2 [34]
External Link
TTD: DZM65T
 Compound Name Inodiftagene vixteplasmid Phase 2 [35]
Synonyms
BC-819
    Click to Show/Hide
External Link
TTD: DE2V3Y
 Compound Name CPX-POM Phase 2 [36]
External Link
TTD: D7K3FB
 Compound Name LY3012212 Phase 2 [37]
Synonyms
Icrucumab
    Click to Show/Hide
External Link
TTD: D0X2RL
 Compound Name CV-301 Phase 2 [8]
External Link
TTD: D0W8FE
 Compound Name ABI-009 Phase 2 [8]
External Link
TTD: D0W3UV
 Compound Name ALT-801 Phase 2 [30]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
External Link
TTD: D0V5JH
 Compound Name INO-5401 Phase 2 [8]
External Link
TTD: D0P2ME
 Compound Name RX-3117 Phase 2 [8]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name BC-819 Phase 2 [38]
External Link
TTD: D0K0KQ
 Compound Name IPI-549 Phase 2 [39]
Synonyms
XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
    Click to Show/Hide
External Link
CID: 91933883
TTD: D0I3LO
 Compound Name B-701 Phase 2 [8]
Synonyms
VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
    Click to Show/Hide
External Link
CID: 95987
TTD: D0G6CF
 Compound Name NC-6004 Phase 2 [8]
External Link
TTD: D0FG2Z
 Compound Name ALT-803 Phase 2 [8]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name Vesigenurtacel-L Phase 2 [40]
External Link
TTD: D0E8QE
 Compound Name BAY1163877 Phase 2 [41]
Synonyms
Rogaratinib
    Click to Show/Hide
External Link
CID: 71611869
TTD: D0E8PR
DrugBank: DB15078
 Compound Name Coxsackievirus A21 Phase 1/2 [30]
Synonyms
Cavatak (TN)
    Click to Show/Hide
External Link
TTD: D0C4BL
 Compound Name OGX-427 Phase 2 [42]
External Link
CID: 71710946
TTD: D0AX1N
 Compound Name PIRITREXIM Phase 2 [43]
Synonyms
72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
    Click to Show/Hide
External Link
CID: 54369
TTD: D09AYQ
DrugBank: DB03695
 Compound Name VesiGel Phase 2 [8]
External Link
TTD: D08LYZ
 Compound Name Instiladrin Phase 2 [44]
External Link
TTD: D07CNY
 Compound Name CDX-1307 Phase 2 [45]
Synonyms
BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
    Click to Show/Hide
External Link
TTD: D04REV
 Compound Name APR-246 Phase 2 [46]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name MV-NIS Phase 1 [8]
Synonyms
MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc
    Click to Show/Hide
External Link
TTD: D01IJJ
 Compound Name 4SCAR-PSMA Phase 1/2 [47]
External Link
TTD: D0VI8T
 Compound Name MAGE-A10 TCR Phase 1/2 [8]
External Link
TTD: D0L1CO
 Compound Name Lx-TB-PstS1 Phase 1/2 [48]
Synonyms
Lx-Bladder
    Click to Show/Hide
External Link
TTD: D0H7LN
 Compound Name 4SCAR-FRa Phase 1/2 [47]
External Link
TTD: D09NUH
 Compound Name ABY-025 Phase 1/2 [49]
External Link
TTD: D08KCJ
 Compound Name ADP-A2M10 Phase 1 [50]
External Link
TTD: DM38KC
 Compound Name TAR-200 Phase 1 [8]
External Link
TTD: D0WM3D
 Compound Name ASG-15ME Phase 1 [51]
External Link
TTD: D0UM4S
 Compound Name Vesimune Phase 2 [52]
External Link
TTD: D0S0ZQ
 Compound Name NEO-PV-01 Phase 1 [8]
External Link
TTD: D0Q6AU
 Compound Name Neo-Urinary Conduit Phase 1 [53]
External Link
TTD: D0B6LP
 Compound Name FPA144 Phase 1 [30]
External Link
TTD: D06NND
 Compound Name Ad-IFN-alpha Phase 1 [54]
Synonyms
Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI
    Click to Show/Hide
External Link
TTD: D03QWG
 Compound Name LNK-754 Phase 1 [55]
Synonyms
LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-
    Click to Show/Hide
External Link
CID: 46208720
TTD: D03BXU
DrugBank: DB12640
 Compound Name example 7 [US8664233] Clinical trial [56]
Synonyms
SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole
    Click to Show/Hide
External Link
CID: 24990553
TTD: D0Y9FX
 Compound Name (S)-DRF-1042 Clinical trial [57]
Synonyms
5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT
    Click to Show/Hide
External Link
CID: 91623363
TTD: D0M8KY
 Compound Name Larotaxel Discontinued in Phase 3 [58]
Synonyms
Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
    Click to Show/Hide
External Link
CID: 6918260
TTD: D0J0RV
DrugBank: DB12984
 Compound Name Keyhole limpet hemocyanin Discontinued in Phase 3 [59]
External Link
TTD: D07UQR
 Compound Name IDM-2 Discontinued in Phase 2/3 [60]
Synonyms
Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma
    Click to Show/Hide
External Link
TTD: D0YW4R
 Compound Name NKS-01 Discontinued in Phase 2 [61]
Synonyms
14alpha-Hydroxy-4-androstene-3,6,17-trione
    Click to Show/Hide
External Link
CID: 6918079
TTD: D0U9LL
 Compound Name S-288310 Discontinued in Phase 1/2 [62]
Synonyms
Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi
    Click to Show/Hide
External Link
TTD: D0Z2KU
 Compound Name Capzola Application submitted [8]
External Link
TTD: D0VO7K
 Compound Name MINAMESTANE Terminated [63]
Synonyms
FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione
    Click to Show/Hide
External Link
CID: 65886
TTD: D0FS9K
 Compound Name CG-8840 Terminated [64]
Synonyms
CV-884
    Click to Show/Hide
External Link
TTD: D02GJE
 Compound Name ET-009 Investigative [65]
External Link
TTD: D0XT3G
 Compound Name TD-6989 Investigative [65]
External Link
TTD: D0V9BX
 Compound Name SL-601 Investigative [65]
External Link
TTD: D0QI1O
 Compound Name ASC-JMZ1 Investigative [65]
External Link
TTD: D0O0II
 Compound Name TD-3633 Investigative [65]
External Link
TTD: D0A5KO
 Compound Name CEL-011 Investigative [65]
External Link
TTD: D09TSX
 Compound Name Debio-1141 Investigative [65]
Synonyms
PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm
    Click to Show/Hide
External Link
TTD: D09OLR
 Compound Name TD-1770 Investigative [65]
External Link
TTD: D08VWJ
 Compound Name Chitosan/IL-12 Investigative [65]
Synonyms
Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute
    Click to Show/Hide
External Link
TTD: D08UZA
 Compound Name BAMLET Investigative [65]
Synonyms
BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune
    Click to Show/Hide
External Link
TTD: D07FCA
 Compound Name TMX-202 Investigative [66]
Synonyms
TMX-20X
    Click to Show/Hide
External Link
TTD: D05TCC
 Compound Name SX-MTR1 Investigative [67]
Synonyms
MTOR modulators (small peptide mimetics, bladder cancer), Serometrix
    Click to Show/Hide
External Link
TTD: D05SOW
 Compound Name AP-300 Investigative [65]
External Link
TTD: D03KIK
 Compound Name BC-821 Investigative [65]
Synonyms
IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell
    Click to Show/Hide
External Link
TTD: D03IQK
 Compound Name OGX-427 + Paclitaxel Investigative [68]
External Link
CID: 91866823
TTD: D00ZBZ
References
Ref 1 FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner. Cell Death Discov. 2021 Nov 1;7(1):329. doi: 10.1038/s41420-021-00724-5.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 6 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
Ref 7 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 9 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
Ref 10 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
Ref 11 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
Ref 12 Clinical pipeline report, company report or official report of Regor Therapeutics
Ref 13 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. doi: 10.1021/acs.jmedchem.7b01261. Epub 2018 Feb 12.
Ref 14 Hedgehog inhibitors: a patent review (2013 - present). Expert Opin Ther Pat. 2015 May;25(5):549-65. doi: 10.1517/13543776.2015.1019864. Epub 2015 Mar 1.
Ref 15 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 16 What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15. doi: 10.1124/jpet.108.149955. Epub 2009 Apr 8.
Ref 17 WO patent application no. 2007,0898,78, Sutures and anti-scarring agents.
Ref 18 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. doi: 10.1016/s0165-6147(02)02071-0.
Ref 19 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. doi: 10.1073/pnas.0708800104. Epub 2007 Dec 11.
Ref 20 Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43. doi: 10.1021/jm049353p.
Ref 21 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 22 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 23 ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health.
Ref 24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034572)
Ref 25 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 27 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 28 Clinical pipeline report, company report or official report of Sesen Bio.
Ref 29 ClinicalTrials.gov (NCT04165317) Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). U.S. National Institutes of Health.
Ref 30 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 31 ClinicalTrials.gov (NCT00598806) Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant for Noninvasive Bladder Cancer. U.S. National Institutes of Health.
Ref 32 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT00406068) Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer. U.S. National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT04492293) An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT03719300) Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT04525131) Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors. U.S. National Institutes of Health.
Ref 37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
Ref 38 ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT03980041) Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275). U.S. National Institutes of Health.
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039425)
Ref 41 ClinicalTrials.gov (NCT04040725) Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
Ref 43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7414).
Ref 44 ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT01094496) A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study). U.S. National Institutes of Health.
Ref 46 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T
Ref 48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031541)
Ref 49 ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health.
Ref 50 Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
Ref 51 ClinicalTrials.gov (NCT01963052) ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer. U.S. National Institutes of Health.
Ref 52 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025521)
Ref 54 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
Ref 55 A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35.
Ref 56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8283).
Ref 57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8261).
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001940)
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014822)
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003076)
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031637)
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002545)
Ref 64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016289)
Ref 65 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 66 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
Ref 67 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
Ref 68 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.